Stock Events

Regeneron Pharmaceuticals 

€920
13
+€12.5+1.38% Today

Statistics

Day High
920
Day Low
911.5
52W High
-
52W Low
-
Volume
11
Avg. Volume
-
Mkt Cap
105.91B
P/E Ratio
26.79
Dividend Yield
-
Dividend
-

Upcoming

Earnings

2MayExpected
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Next
9.48
10.51
11.53
12.56
Expected EPS
10.2
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RGO.F. It's not an investment recommendation.

Analyst Ratings

972.67Average Price Target
The highest estimate is €1,184.
From 13 ratings within the last 6 months. This is not an investment recommendation.
Buy
77%
Hold
23%
Sell
0%

About

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Show more...
CEO
Dr. Leonard S. Schleifer M.D., Ph.D.
Employees
13450
Country
US
ISIN
US75886F1075
WKN
000881535

Listings